Des Jarlais
Don C. Des Jarlais, PhD
CDUHR - Associate Director, Infectious Disease Epidemiology and Social-behavioral Theory Core
NYU School of Global Public Health - Professor
PhD, Social Psychology, University of Michigan, Ann Arbor
BA, Behavioral Science, Rice University
Research Interests
Injecting drug use, Epidemiology, HIV, HCV, Research synthesis
For over 30 years Don Des Jarlais has been conducting HIV/AIDS research among persons who inject drugs (PWID). He is PI of the “Risk Factors” study (R01DA003574), which was instrumental in tracking the HIV/AIDS epidemic in New York City. This study has been funded by the National Institute on Drug Abuse since 1983 and is the longest continuously funded study on HIV/AIDS in persons who use drugs. He has conducted HIV/AIDS research nationally (Seattle, CDC CIDUS studies, national syringe exchange survey) and internationally (in over 20 different countries). He has served as a consultant on these issues to the World Health Organization, the National Institutes of Health and the U.S. Centers for Disease Control and Prevention.
Principal Investigator, Combined Prevention to Reduce Initiation Into Injecting Drug Use. Active
Principal Investigator, DRIVE (Drug Use and Blood-Borne Infections in Vietnam): Combined Prevention and Care to End the HIV Epidemic Among People Who Inject Drugs in Haiphong, Vietnam. Active
Principal Investigator, Risk Factors for AIDS among Persons Who Inject Drugs: HIV and COVID-19. Active
Principal Investigator, Barriers to Reason: Laws Impacting HIV Prevention Efforts among IDUs in the United States. Completed
Principal Investigator, Combined HIV Prevention for PWID and Future Collaborative Research in Vietnam. Completed
Principal Investigator, Evaluating ART for All HIV Seropositives: Can It Work with the Hardest Cases?. Completed
Principal Investigator, Expanded Syringe Access Program: NY Evaluation (ESAP). Completed
Principal Investigator, HIV Infection in Ethnic Minority IDUs: An International Systematic Review. Completed
Principal Investigator, HIV Transmission among Injecting and Non-Injecting Drug Users in Tallinn, Estonia. Completed
Principal Investigator, Multiple HIV Prevention Packages for IDUs in Estonia. Completed
Principal Investigator, National Study of Syringe Exchange Programs. Completed
Principal Investigator, WHO Survey Coordinating Center, Drug Injecting Study – Phase 2. Completed


Barnes DM, Xu S, Cleland CM, McKnight C, Des Jarlais D (2022).
Recurrent injecting drug use as a mediator between psychiatric disorder and non-fatal overdose
Substance Use and Misuse, 57 (8), 1248-1256. doi: 10.1080/10826084.2022.2076877.

Aronson ID, Zhang J, Rajan S, Marsch LA, Bugaighis M, Ibitoye MO, Chernick LS, Des Jarlais DC (2022).
Automated substance use/sexual risk reporting and HIV test acceptance among emergency department patients aged 13-24 years
AIDS and Behavior, 26 (5), 1544-1551. doi: 10.1007/s10461-021-03507-2. PMCID: PMC9007819.

Hwahng SJ, Allen B, Zadoretzky C, Doucet HB, McKnight C, Des Jarlais D (2022).
Thick trust, thin trust, social capital, and health outcomes among trans women of color in New York City
International Journal of Transgender Health, 23 (1-2), 214-231. doi: 10.1080/26895269.2021.1889427.

Le SM, Trouiller P, Huong DT, Oanh KTH, Khue PM, Vallo R, Rapoud D, Quillet C, Nguyen TL, Nguyen QD, Tranh NTT, Giang HT, Feelemyer J, Vinh VH, Moles JP, Doan HQ, Laureillard D, Des Jarlais DC, Nagot N, Michel L, DRIVE Study Team (2022).
Development and assessment of a community-based screening tool for mental health disorders among people who inject drugs
Drug and Alcohol Review, 41 (3), 697-705. doi: 10.1111/dar.13402.

Behrends CN, Lu X, Corry GJ, LaKosky P, Prohaska SM, Glick SN, Kapadia SN, Perlman DC, Schackman BR, Des Jarlais DC (2022).
Harm reduction and health services provided by syringe services programs in 2019 and subsequent impact of COVID-19 on services in 2020
Drug and Alcohol Dependence, 232, 109323. doi: 10.1016/j.drugalcdep.2022.109323. PMCID: PMC8772135.


Des Jarlais DC, Huong DT (2018).
Ending HIV epidemics among people who inject drugs in LMICs
Lancet, 392 (10149), 714-719. doi: 10.1016/S0140-6736(18)31721-5.

Dr. Des Jarlais' ResearchGate Profile
Selected Press